[go: up one dir, main page]

WO2000056298A3 - Traitement de la maladie de la lyme au moyen de formulations de glycosaminoglycans polysulfates - Google Patents

Traitement de la maladie de la lyme au moyen de formulations de glycosaminoglycans polysulfates Download PDF

Info

Publication number
WO2000056298A3
WO2000056298A3 PCT/US2000/006382 US0006382W WO0056298A3 WO 2000056298 A3 WO2000056298 A3 WO 2000056298A3 US 0006382 W US0006382 W US 0006382W WO 0056298 A3 WO0056298 A3 WO 0056298A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
lyme disease
polysulfated glycosaminoglycan
formulations
glycosaminoglycan formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/006382
Other languages
English (en)
Other versions
WO2000056298A2 (fr
WO2000056298A9 (fr
Inventor
Richard P Lawrence
Ralf A Lange
Mary Jane Helenek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
American Regent Inc
Original Assignee
Luitpold Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luitpold Pharmaceuticals Inc filed Critical Luitpold Pharmaceuticals Inc
Publication of WO2000056298A2 publication Critical patent/WO2000056298A2/fr
Publication of WO2000056298A3 publication Critical patent/WO2000056298A3/fr
Anticipated expiration legal-status Critical
Publication of WO2000056298A9 publication Critical patent/WO2000056298A9/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur des compositions et sur des procédés de traitement de la maladie de la Lyme associée à des symptômes articulaires et arthritiques, ces procédés de traitement étant effectués au moyen de glycosaminoglycans polysulfatés.
PCT/US2000/006382 1999-03-19 2000-03-13 Traitement de la maladie de la lyme au moyen de formulations de glycosaminoglycans polysulfates Ceased WO2000056298A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27199199A 1999-03-19 1999-03-19
US09/271,991 1999-03-19

Publications (3)

Publication Number Publication Date
WO2000056298A2 WO2000056298A2 (fr) 2000-09-28
WO2000056298A3 true WO2000056298A3 (fr) 2001-05-03
WO2000056298A9 WO2000056298A9 (fr) 2001-11-29

Family

ID=23037944

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/006382 Ceased WO2000056298A2 (fr) 1999-03-19 2000-03-13 Traitement de la maladie de la lyme au moyen de formulations de glycosaminoglycans polysulfates

Country Status (1)

Country Link
WO (1) WO2000056298A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
DE10053053A1 (de) * 2000-10-19 2002-05-16 Knoell Hans Forschung Ev Pharmazeutische Formulierungen zur Hemmung von entzündlichen Arthritiden
EP4580751A2 (fr) * 2022-09-29 2025-07-09 Adora Animal Health Corporation Formulations pénétrant dans la peau de glycosaminoglycanes sulfatés et fragments dérivés de celles-ci pour le traitement de la douleur et d'autres états médicaux

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4524066A (en) * 1981-05-11 1985-06-18 Luitpold-Werk Chemisch-Pharmazeutische Fabrik Process for the preparation of injectable chondroitin polysulfate
EP0418827A1 (fr) * 1989-09-19 1991-03-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Vaccin contre la maladie de Lyme
US5036056A (en) * 1987-07-08 1991-07-30 Martin Kludas Methods for treating damaged corneal, uterine, or cartilage tissue
EP0441003A2 (fr) * 1989-12-20 1991-08-14 Lawrence Goldman Medicaments ophtalmiques
WO1998024477A1 (fr) * 1996-12-06 1998-06-11 Amgen Inc. Therapie combinee utilisant un inhibiteur de l'il-1 pour traiter les maladies induites par l'il-1
US5888514A (en) * 1997-05-23 1999-03-30 Weisman; Bernard Natural composition for treating bone or joint inflammation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4524066A (en) * 1981-05-11 1985-06-18 Luitpold-Werk Chemisch-Pharmazeutische Fabrik Process for the preparation of injectable chondroitin polysulfate
US5036056A (en) * 1987-07-08 1991-07-30 Martin Kludas Methods for treating damaged corneal, uterine, or cartilage tissue
EP0418827A1 (fr) * 1989-09-19 1991-03-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Vaccin contre la maladie de Lyme
EP0441003A2 (fr) * 1989-12-20 1991-08-14 Lawrence Goldman Medicaments ophtalmiques
WO1998024477A1 (fr) * 1996-12-06 1998-06-11 Amgen Inc. Therapie combinee utilisant un inhibiteur de l'il-1 pour traiter les maladies induites par l'il-1
US5888514A (en) * 1997-05-23 1999-03-30 Weisman; Bernard Natural composition for treating bone or joint inflammation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BERKOW R., FLETCHER A.J.: "The Merck Manual of diagnosis and therapy, sixteenth edition.", 1992, MERCK RESEARCH LABORATORIES, RAHWAY, NEW YORK, XP002152604, 215310 *
BUDAVARI S., O'NEIL M., SMITH A., HECKELMAN P.: "The Merck Index Eleventh Edition", 1989, MERCK & CO. , INC., RAHWAY, N.J., XP002152848 *
KONNO S (REPRINT) ET AL: "REGULATORY EFFECTS OF HEPARIN ON LYMPHOCYTE-PROLIFERATION IN LYME -DISEASE PATIENTS", JOURNAL OF IMMUNOLOGY, (15 APR 1993) VOL. 150, NO. 8, PART 2, PP. A155. ISSN: 0022-1767., NEW YORK MED COLL, DEPT MED, VALHALLA, NY, 10595;NEW YORK MED COLL, DEPT BIOCHEM & MOLEC BIOL, VALHALLA, NY, 10595, XP000961371 *
LEONG JOHN M ET AL: "Hemagglutination and proteoglycan binding by the Lyme disease spirochete, Borrelia burgdorferi.", INFECTION AND IMMUNITY, vol. 63, no. 3, 1995, pages 874 - 883, XP000957831, ISSN: 0019-9567 *
WADSTROEM TORKEL ET AL: "Glycosaminoglycan-binding microbial proteins in tissue adhesion and invasion: Key events in microbial pathogenicity.", JOURNAL OF MEDICAL MICROBIOLOGY, vol. 48, no. 3, March 1999 (1999-03-01), pages 223 - 233, XP000957766, ISSN: 0022-2615 *

Also Published As

Publication number Publication date
WO2000056298A2 (fr) 2000-09-28
WO2000056298A9 (fr) 2001-11-29

Similar Documents

Publication Publication Date Title
AU2085201A (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
AU2001271973A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2003034984A9 (fr) Compositions et procedes pour le diagnostic et le traitement d'affections intestinales inflammatoires
AU4539097A (en) Compositions for the treatment of rheumatoid-based arthritic diseases
WO2000074689A8 (fr) Fraction de gel non fermentee des enveloppes de graines de psyllium
AU7389300A (en) Methods of administration of glycopyrrolate compositions
AU2002318759A1 (en) Remedies for diseases with bone mass loss having EP4 agonists as the active ingredient
AU2001269478A1 (en) Hyaluronic acid oligosaccharide fractions and drugs containing the same
AU3702000A (en) Phenytoin sodium pharmaceutical compositions
CA2343732A1 (fr) .delta.-lactones .gamma.-phenyl-substituees, leurs analogues, et leurs utilisations
AU2035401A (en) Lubricant combination and process for the preparation thereof
AU2001246510A1 (en) Glycosaminoglycans derived from the k5 polysaccharide having high anticoagulant and antithrombotic activity and process for their preparation
AU2001251507A1 (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
AU2011501A (en) Benzimidazoles, production thereof and the use thereof as antithrombotic
WO2000056298A3 (fr) Traitement de la maladie de la lyme au moyen de formulations de glycosaminoglycans polysulfates
AU1953701A (en) Methods and compositions for treatment of inflammatory disease
WO2000042987A8 (fr) Produits de recombinaison vesiculaires cibles utilises pour la protection des cellules et le traitement d'infections provoquees par $i(helicobacter pylori)
AU3434601A (en) Compositions and methods for the treatment of immune related diseases
AU2593597A (en) Compositions for the diagnosis and treatment of chediak-higashi syndrome
IL139531A0 (en) Human antithrombin iii, methods for the production thereof and pharmaceutical compositions containing the same
AU4515001A (en) Compositions and methods for locally treating inflammatory diseases
AU2001283199A1 (en) Methods and compositions for the diagnosis and treatment of brown adipose cell disorders
AU2001274601A1 (en) Preventives or remedies for heart failure
AU2001256998A1 (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
AU2001251508A1 (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: C2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGE 1/1, DRAWINGS, REPLACED BY A NEW PAGE 1/1; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

122 Ep: pct application non-entry in european phase